Edward Fishman: The Collapse of the Oil Empire?
EPISODE SUMMARY Podcast host Alex Gabuev is joined by Edward Fishman, a senior research scholar at the Center on Global Energy Policy at Columbia University,…
Thought Leader: Edward Fishman
Bet Big on Treatments for Coronavirus
By Scott Gottlieb (original source Wall Street Journal)
“Some imagine that the coronavirus will run its tragic course in the spring, with the direst results avoided by intense social-distancing and other mitigation efforts, and then our lives can more or less return to normal in the summer.
But that isn’t realistic. Even if new cases start to stall in the summer heat, the virus will return in the fall, and so will fresh risk of large outbreaks and even a new epidemic. People will still be reluctant to crowd into stores, restaurants or arenas. Schools may remain closed. The public’s fears won’t relent simply because there are fewer new cases. We’ll be running an 80% economy.
The only way out is with technology. Aggressive surveillance and screening can help warn of new infection clusters that could turn into outbreaks, but that won’t be enough. A vaccine could beat the virus, but there won’t be one this year. The best near-term hope: an effective therapeutic drug. That would be transformative, and it’s plausible as soon as this summer. But the process will have to move faster.”
Click here to read more
Relevant and recent posts
Leana Wen: How long does covid booster protection last?
More evidence highlighting the benefit, and limitations, of covid-19 vaccines. After the Centers for Disease Control and Prevention shifted its coronavirus vaccine guidance from a…
Thought Leader: Leana Wen
Dr. Sanjay Gupta: How Wearable Tech Transforms Health
We’ve come a long way in integrating technology into our daily lives, but could wearable tech actually help you live longer? From detecting heartbeat irregularities to flagging signs of…
Thought Leader: Sanjay Gupta
More with this speaker
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb